Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

CORT 10.23.2024

Full Press ReleaseSEC FilingsOur CORT Tweets

About Gravity Analytica

Recent News

  • 01.13.2025 - MONARCH: a Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH)
  • 12.30.2024 - Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism
  • 12.16.2024 - Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism

Recent Filings

  • 01.14.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.10.2025 - 144 Report of proposed sale of securities
  • 12.30.2024 - EX-99.1 EX-99.1

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Oct. 23, 2024--Corcept Therapeutics Incorporated(NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update onOctober 30, 2024. The company will also host a conference call that day at5:00 p.m. Eastern Time(2:00 p.m. Pacific Time).

Conference Call Information

Participants must register in advance of the conference call by clickinghere.Upon registering, each participant will receive a dial-in number, and a unique access PIN. Each access PIN will accommodate one caller.

Additionally, a listen-only webcast will be available by clickinghere.

A replay of the call will be available on the Investors / Events tab ofCorcept.com.

AboutCorcept Therapeutics

For over 25 years, Corcept’s focus on cortisol modulation and its potential to treat patients with a wide variety of serious disorders has led to the discovery of more than 1,000 proprietary selective cortisol modulators. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, amyotrophic lateral sclerosis (ALS) and liver disease. InFebruary 2012, the company introduced Korlym®, the first medication approved by theU.S. Food and Drug Administrationfor the treatment of patients with Cushing’s syndrome. Corcept is headquartered inRedwood City, California. For more information, visitCorcept.com.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241023550946/en/

Investor inquiries:ir@corcept.comMedia inquiries:communications@corcept.comwww.corcept.com

Source:Corcept Therapeutics Incorporated

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com